37 results about "Medetomidine" patented technology

The invention relates to the technical field of biochemical engineering, in particular to a medetomidine hapten, a preparation method of the medetomidine hapten, a medetomidine antigen, a preparation method of the medetomidine antigen, a kit and a medetomidine detection method. The medetomidine hapten is selected from a compound shown in the following structural formula: # imgabs0 #, q is any integer between 1 and 5, and R represents amido or carbonyl. The medetomidine hapten can be used for synthesizing a medetomidine antigen, so that the medetomidine hapten can be used for immunizing to generate an antibody, and adverse reaction caused by using medetomidine or hydrochloride thereof is reduced. Meanwhile, the medetomidine can be applied to rapid diagnosis products such as kits, medetomidine can be simply, conveniently and rapidly detected, and then the phenomenon of drug abuse can be effectively reduced.

The invention relates to a dexmedetomidine hydrochloride microneedle which is prepared from a drug-loading needle body layer and a substrate layer, the volume ratio of the drug-loading needle body layer to the substrate layer is 1: 100-200, the drug-loading needle body layer is prepared from polyvinylpyrrolidone and dexmedetomidine hydrochloride according to the mass ratio of 1-15: 1, and the substrate layer is prepared from polyethylene glycol diacrylate through photo-crosslinking. The dexmedetomidine hydrochloride microneedle disclosed by the invention has the advantages that the dexmedetomidine hydrochloride microneedle takes effect quickly, is long in drug effect maintenance time, is non-irritant to skin, avoids infection risk, realizes percutaneous precise administration of dexmedetomidine hydrochloride, and remarkably improves bioavailability and medication safety and effectiveness of dexmedetomidine hydrochloride.

The invention belongs to the field of high polymer materials, and particularly relates to a polyphenylene sulfide composite membrane for seawater corrosion prevention and antibiosis and a preparation method thereof. The invention provides the high-toughness nano-metal molybdate crystal composite polyphenylene sulfide film protection layer, and medetomidine is optionally further added, so that the film protection layer has the functions of corrosion prevention, marine organism adhesion prevention and the like, the corrosion of the marine environment to the surface of a ship is reduced, the adhesion of marine organisms to the surface of the ship is reduced, and the service life of the ship is prolonged. Normal operation of the ship is ensured, maintenance cost is reduced, and service life of the ship is prolonged.

The invention discloses a dexmedetomidine derivative, application of the dexmedetomidine derivative and a quality control or detection method of a dexmedetomidine transdermal patch preparation, the dexmedetomidine derivative can be used as a standard substance for quality control of the dexmedetomidine transdermal patch preparation, and meanwhile, the invention provides a preparation method of the dexmedetomidine derivative.

The invention provides a medetomidine preparation method, which comprises: S1, taking 2, 3-dimethyl benzaldehyde as an initial raw material, and carrying out a reaction on the 2, 3-dimethyl benzaldehyde and methylmagnesium chloride to generate 1-(2, 3-dimethyl phenyl) ethanol; s2, excessive silyl group protected imidazole is added into a reaction system in the step S1, and an activated [1-(2, 3-dimethylphenyl) ethyoxyl] silyl ether intermediate is obtained; taking trimethylsilyl trifluoromethanesulfonate as a catalyst, carrying out a Friedel-Crafts reaction with silyl-protected imidazole, and after the reaction is finished, carrying out post-treatment on the reaction liquid to obtain a medetomidine crude product. 2, 3-dimethyl benzaldehyde is adopted as a starting raw material, medetomidine is prepared through a one-pot method, raw materials are cheap, reaction steps are short, the production cost is greatly reduced, TMSOTf is adopted as a catalyst in the Friedel-Crafts reaction, the reaction is efficient, it can be effectively avoided that in the aftertreatment process of a traditional catalyst titanium tetrachloride, a large number of titanic acid colloidal solid insoluble substances are formed, and the yield of medetomidine is increased. The problem that post-treatment layering is difficult is solved, and the yield is increased.

This invention relates to a medemididine hapten, a complete antigen, and their preparation methods and applications. The structure of the medemididine hapten is shown in Formula I. The preparation method of the medemididine hapten includes: (1) substituting medemididine with ethyl 3-bromopropionate to obtain intermediate 2; (2) adding sodium hydroxide to deprotect the ester group to obtain medemididine hapten 3. The structure of the complete antigen is shown in Formula II. The preparation method of the complete antigen includes: coupling the medemididine hapten with a carrier protein to obtain the complete antigen. This invention discloses a method for preparing medemididine hapten and complete antigen. The synthesis steps are simple and effective, and it can be used in immunoassay. Among them, colloidal gold immunochromatography is simple to operate, has a short detection time, high specificity, and good reproducibility, which can meet the domestic demand for immunoassay of medemididine.

The present invention relates to a kind of dexmedetomidine hydrochloride orally disintegrating film, in which the orally disintegrating film contains dexmedetomidine hydrochloride 0.1-10% and film-forming material 90%-99.9% by weight, wherein the film-forming material is selected from any one of copolyvidone, polyethylene caprolactam polyvinyl acetate polyethylene glycol graft copolymer, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, polyoxyethylene, povidone, and poloxamer or a combination thereof. The dexmedetomidine hydrochloride orally disintegrating film of the present invention has fast disintegration time in the oral cavity, good mechanical extrusion performance, good film-forming performance, high content uniformity, meets the requirements such as cutting, packaging, transportation and clinical use, significantly improves its dissolution and dissolution rate, stability and bioavailability, and does not need to be taken with water, significantly improves the compliance of children patients, and ensures safe and effective medication.

The application provides a dexmedetomidine hydrochloride soluble microneedle; the dexmedetomidine hydrochloride soluble microneedle comprises a substrate and a drug-loaded needle body, the drug-loaded needle body comprises dexmedetomidine hydrochloride and a penetration enhancer; the penetration enhancer comprises at least two of laurocapram, polyvinylpyrrolidone and polysorbate; the weight average molecular weight of the polyvinylpyrrolidone is 2000 Da to 13000 Da. The dexmedetomidine hydrochloride soluble microneedle provided by the application can significantly improve the peak drug concentration after transdermal delivery under the promotion of the penetration enhancer, has a short onset time and a long duration, and can achieve the effects of rapid release, rapid onset and sustained effectiveness.

The invention provides a medetomidine artificial hapten, an artificial antigen as well as a preparation method and application of the medetomidine artificial hapten and the artificial antigen. Specifically, the invention provides a medetomidine artificial hapten of formula (X), the artificial hapten maximally retains the characteristic structure of medetomidine, has an active group capable of being coupled with carrier protein, can be used as an antigenic determinant, and has high sensitivity during immunoassay; furthermore, the invention provides a medetomidine artificial antigen based on the medetomidine artificial hapten, and the medetomidine artificial antigen can be applied to colloidal gold immunochromatography detection of medetomidine and has relatively high sensitivity, detection gradient and relatively good specificity.

The invention provides a composition for relieving beef cattle transportation stress syndrome and application thereof, the composition is prepared by premixing dexmedetomidine hydrochloride, gastrodin and normal saline for injection according to the mass concentration ratio, the concentration of dexmedetomidine hydrochloride is 60-65 g / mL, and the concentration of gastrodin is 20-30 mg / mL. The composition is applied to beef cattle before transportation, the composition is intramuscularly injected, and the total injection volume is 10-20 mL. After the composition is injected before beef cattle transportation, immune dysfunction can be effectively improved, excessive HPA axis activation is inhibited, cortisol secretion is reduced, oxidative damage is relieved, and the stability of intestinal flora is maintained, so that inflammation is relieved, nervous excitability is reduced, calming and anxiety resisting effects are achieved, beef cattle transportation stress response is reduced, and the beef cattle transportation effect is improved. And the method is simple to operate and low in cost, and provides theoretical and practical support for preventing the beef cattle transportation stress syndrome.

The invention provides a dexmedetomidine sustained-release microneedle and a preparation process thereof. The dexmedetomidine sustained-release microneedle comprises a first section of matrix containing 3.5 W% of hyaluronic acid and 3.5 W% of polyvinylpyrrolidone, the matrix is degraded within about 10 minutes and can provide rapid preliminary drug release, and a second section of matrix containing 15 W% of polyvinyl methyl ether-alt-maleic acid, the matrix is slowly degraded within about 3 hours and can provide rapid preliminary drug release. And sustained drug release is provided. According to the dexmedetomidine sustained-release microneedle and the preparation process thereof, the sustained-release microneedle adopts a two-section structure, and high-performance materials such as hyaluronic acid, polyvinylpyrrolidone and polyvinyl methyl ether-alt-maleic acid are combined, so that the release process of a medicine is divided into two stages of quick effect taking and long-acting sustained release. The first section of matrix is degraded within 10 minutes, 30% of medicine can be rapidly released, and rapid effect taking is achieved.

The invention relates to a dexmedetomidine film agent and a preparation method thereof, the prescription components of the dexmedetomidine film agent comprise dexmedetomidine or a pharmaceutically acceptable salt thereof and a film-forming agent, and the mass ratio of dexmedetomidine to the film-forming agent is 1: (20-200); the film-forming agent is glucose polymer ether. The glucose polymer ether can be a cellulose ether derivative and / or a starch ether derivative. When the glucose polymer ether is a starch ether derivative, the formula further comprises a plasticizer. The preparation method comprises the following steps: coating slurry to prepare a film, and drying; the slurry comprises the prescription components of the dexmedetomidine and water. And the obtained film agent product is stable in quality.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention discloses a preparation method of dexmedetomidine hydrochloride. First, 2', 3'-dimethylacetophenone is used as raw material. Under Lewis acid catalysis, chlorination reaction occurs with dimethylchlorosilane to synthesize 1-(1-chloroethyl)-2,3-dimethylbenzene. Then, under chiral catalyst catalysis, cross-reduction coupling reaction occurs with 4-iodoimidazole, and finally salification is performed to obtain dexmedetomidine hydrochloride with an enantiomeric excess of up to 99%. The method has the advantages of easy availability of raw materials, simple operation, mild reaction conditions, short synthesis route, high yield, good stereoselectivity, and good economic and social benefits.

The invention provides a dexmedetomidine transdermal patch which comprises a backing layer, a release film and a polymer matrix layer arranged between the backing layer and the release film, the polymer matrix layer comprises dexmedetomidine, povidone and a pressure-sensitive adhesive, based on the total mass of the polymer matrix layer, the dexmedetomidine accounts for 4-10%, the povidone accounts for 5-10%, and the pressure-sensitive adhesive accounts for 5-10%. The povidone accounts for 2-12%, and the pressure-sensitive adhesive accounts for 78-94%; the pressure-sensitive adhesive comprises at least one of polymers containing carboxyl or hydroxyl functionalization.

A preparation method of an external patch for preoperative sedation relates to the field of medical preparations containing organic effective components, and sequentially comprises the steps of preparing a main component pretreatment substance, preparing a matrix solution, preparing an ointment-containing paste and synthesizing the patch, the preparation method of the main component pretreatment substance comprises the following steps: preparing a mixed liquid by taking dexmedetomidine hydrochloride and floperidol as main components, carrying out spray granulation to obtain a composite solid dispersion, crushing the composite solid dispersion into powder, and mixing and stirring the powder with paraffin oil and superfine silica powder. In the patch prepared from dexmedetomidine hydrochloride and floperidol, the effective components can quickly penetrate through the skin mucous membrane, so that the effect of quickly taking effect is achieved, and a good sedative effect is achieved. The dispersion uniformity of main components in the patch is excellent, the RSD is within 2%, and the effect consistency of the patch is guaranteed. According to the dexmedetomidine hydrochloride tablet, the stability of dexmedetomidine hydrochloride is effectively improved, components are prevented from being decomposed in the long-term storage process, other impurities are not generated, and the shelf life is effectively prolonged to 24 months.

A superhydrophobic anti-fouling crayon comprises a composition of capsaicin, wax, polydimethylsiloxane (PDMS), polytetrafluoroethylene (PTFE), and triglyceride, where the crayon is water insoluble, superhydrophobic, and transparent to electronic sensor and antennae signals. The crayon is rubbed onto the marine surface such that a layer of the composition of the crayon is applied thereto to produce a durable coating that inhibits fouling.

The present disclosure relates to a dexmedetomidine microneedle patch, a method for preparing the same, and application thereof. The dexmedetomidine microneedle patch includes a substrate and a needle body disposed on a surface of the substrate, wherein the needle body includes dexmedetomidine hydrochloride, a matrix material, and a permeation enhancer. The permeation enhancer includes one or more of dodecyl-β-D-maltoside, ethylenediaminetetraacetic acid, and tetrahydropiperine.

This application relates to the use of dexmedetomidine in the preparation of a drug for protecting the glycocalyx structure of lung tissue, a formulation thereof, and its application, belonging to the field of lung injury technology. This application provides a formulation for protecting the glycocalyx structure of lung tissue, the formulation containing dexmedetomidine, which can protect the glycocalyx structure of lung tissue, thereby reducing lung injury and can be used to treat lung injury.

The present disclosure relates to methods of using dexmedetomidine for therapeutic purposes wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at least once a day for at least two consecutive days.

The invention belongs to the technical field of anesthetic drugs, and particularly relates to an anesthetic drug and a preparation method thereof. The anesthetic is prepared by mixing 1000 parts by weight of bupivacaine liposome injection, 0.5-1 part by weight of magnesium sulfate and 3-5 parts by weight of dexmedetomidine hydrochloride. Wherein magnesium sulfate and dexmedetomidine hydrochloride are auxiliary agents, so that the anesthesia onset time is shortened. The anesthetic prepared by the invention is smaller in side effect, quick in effect taking and long in maintenance time, the injection frequency of the anesthetic can be reduced, the infection risk and the nursing cost can be reduced, the anesthetic effect is good, and the application prospect is wide.

The present invention relates to a method for the production of a liquid formulation suitable for intravenous administration in a glass vial with a rubber stopper, where the formulation is dexmedetomidine hydrochloride in water for injection (WFI). The method comprises steps of introducing WFI into a preparation vessel, passing an inert gas through the WFI until a dissolved oxygen content of 1 ppm or less is obtained, adding and dissolving a quantity of sodium chloride and dexmedetomidine hydrochloride, filtering the dexmedetomidine hydrochloride solution, and filling one or more glass vials with the liquid dexmedetomidine hydrochloride-in-WFI formulation before closing said vials with a rubber stopper and sealing the vials. The invention also relates to a sterile liquid formulation of dexmedetomidine hydrochloride in WFI, and its applications.

A solid particle comprising a co-precipitate of a metal compound or metalloid compound with medetomidine or an enantiomer or salt of medetomidine; anti-fouling agents and anti-fouling coating formulations containing such particles; an antifouling coating obtained by using the coating formulation; and an object having the coating on at least part of the surface. A method for preparing the particles and the formulation.

The application discloses application of Phillygenin combined with dexmedetomidine in improving myocardial ischemia-reperfusion injury and belongs to the technical field of drug development. The drug composition is composed of Phillygenin and dexmedetomidine; the combined use of Phillygenin and dexmedetomidine can reduce myocardial ischemia-reperfusion injury, and compared with the use of Phillygenin or dexmedetomidine alone, the combined use of Phillygenin and dexmedetomidine has a synergistic effect. The combined use of Phillygenin and dexmedetomidine can prevent and treat myocardial ischemia-reperfusion injury and provides a new target for the treatment of myocardial ischemia-reperfusion.

Methods and compositions, e.g., compositions for intravenous administration, comprising dextroamphetamine and / or lisdexamfetamine for use in reversal of dexmedetomidine sedation.

This invention relates to the field of healthcare informatics technology and discloses a dexmedetomidine MDK-mediated pathway network inference system. The system comprises a data acquisition module that receives infusion sequences, pressure monitoring streams, and biochemical data; a time feature alignment unit that identifies infusion jump characteristics to establish the physical excitation origin and calculates pressure response delay to determine communication latency; a dynamic phase calibration module that performs time-domain translation based on this latency and extracts the elastic phase deviation of metabolic lag through cross-correlation calculations; and a regulatory topology construction module that eliminates time offsets between monitoring data and calculates causal weights to establish the regulatory pathway topology. This invention uses physical calibration to eliminate communication latency interference from devices, achieving precise phase locking at the physiological level, resolving inference errors caused by clock offsets, enhancing recognition accuracy under low signal-to-noise ratios, and providing accurate pathway feedback maps for clinical decision-making.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.

A superhydrophobic anti-fouling crayon comprises a composition of capsaicin, wax, polydimethylsiloxane (PDMS), polytetrafluoroethylene (PTFE), and triglyceride, where the crayon is water insoluble, superhydrophobic, and transparent to electronic sensor and antennae signals. The crayon is rubbed onto the marine surface such that a layer of the composition of the crayon is applied thereto to produce a durable coating that inhibits fouling.

Methods and compositions, e.g., compositions for intravenous administration, comprising dextroamphetamine and / or lisdexamfetamine for use in reversal of dexmedetomidine sedation.

The invention relates to a method for detecting the content of impurity chloromethane in a dexmedetomidine hydrochloride intermediate. According to the method, a chromatographic column is GL # imgabs0 # wanda cap 5, and 5%-phenyl-95% dimethyl polysiloxane is adopted as a stationary liquid; the temperature of a sample inlet is 230-250 DEG C; the temperature of a detection port is 240-260 DEG C (the detector is FID); the split ratio is (2-20): 1; the flow velocity is 2-3 ml / min; the initial temperature is 20-50 DEG C, the temperature is maintained for 3 min, and the temperature is increased to 240 DEG C at the heating rate of 45-55 DEG C / min and maintained for 15 min. The separation degree R of impurity chloromethane can be larger than or equal to 1.5, the impurity content RSD of chloromethane is smaller than or equal to 2.0 after a chloromethane sample is continuously injected for five times, the sample injection repeatability is good, the durability of the method is good, and the method can be used for quality control of dexmedetomidine hydrochloride intermediates.